Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery.

High density lipoproteins (HDLs) are dynamic natural nanoparticles best known for their role in cholesterol transport and the inverse correlation that exists between blood HDL levels and the risk of developing coronary heart disease. In addition, enhanced HDL-cholesterol uptake has been demonstrated in several human cancers. As such, the use of HDL as a therapeutic and as a vehicle for systemic delivery of drugs and as imaging agents is increasingly important. HDLs exist on a continuum from the secreted HDL-scaffolding protein, apolipoprotein A-1 (Apo A1), to complex, spherical "mature" HDLs. Aspects of HDL particles including their size, shape, and surface chemical composition are being recognized as critical to their diverse biological functions. Here we review HDL biology; strategies for synthesizing HDLs; data supporting the clinical use and benefit of directly administered HDL; a rationale for developing synthetic methods for spherical, mature HDLs; and, the potential to employ HDLs as therapies, imaging agents, and drug delivery vehicles. Importantly, methods that utilize nanoparticle templates to control synthetic HDL size, shape, and surface chemistry are highlighted.

[1]  R. Hovorka,et al.  Effects of intravenous infusion of lipid-free apo A-I in humans. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[2]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[3]  T. Ishida,et al.  Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats , 2010, Pharmaceutics.

[4]  Douglas P. Zipes,et al.  Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 10th Edition , 2011 .

[5]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[6]  C. Nelson,et al.  Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration‐resistant prostate cancer in a mouse xenograft model , 2010, The Prostate.

[7]  S. Reddy,et al.  Structure and function of HDL mimetics. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[8]  P. Barter,et al.  The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. , 1994, The Journal of biological chemistry.

[9]  E. Schaefer,et al.  Metabolic and functional relevance of HDL subspecies , 2011, Current opinion in lipidology.

[10]  G. Juliusson,et al.  Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. , 1994, Blood.

[11]  N. Kuyucu Amphotericin B use in children: conventional and lipid-based formulations , 2011, Expert review of anti-infective therapy.

[12]  W. Frishman,et al.  Apolipoprotein A-I Mimetic Peptides: A Potential New Therapy for the Prevention of Atherosclerosis , 2010, Cardiology in review.

[13]  D. Sviridov,et al.  Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. , 2009, Journal of the American College of Cardiology.

[14]  A. Jonas,et al.  Lipid transfers between reconstituted high density lipoprotein complexes and low density lipoproteins: effects of plasma protein factors. , 1988, Journal of lipid research.

[15]  T. Xia,et al.  Toxic Potential of Materials at the Nanolevel , 2006, Science.

[16]  K. Pritchard,et al.  D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma[S] , 2011, Journal of Lipid Research.

[17]  A. Folsom,et al.  High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). , 2008, Blood.

[18]  D. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.

[19]  S. Kaul,et al.  High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.

[20]  Nicola J. Armstrong,et al.  Haemolysis during Sample Preparation Alters microRNA Content of Plasma , 2011, PloS one.

[21]  G. Jenster,et al.  Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.

[22]  Chad A. Mirkin,et al.  Gene regulation with polyvalent siRNA-nanoparticle conjugates. , 2009, Journal of the American Chemical Society.

[23]  M. Oda,et al.  Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B Published, JLR Papers in Press, November 28, 2005. , 2006, Journal of Lipid Research.

[24]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[25]  A. Kontush,et al.  Antiatherogenic small, dense HDL—guardian angel of the arterial wall? , 2006, Nature Clinical Practice Cardiovascular Medicine.

[26]  D. Sviridov,et al.  Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque , 2008, Circulation research.

[27]  A. Jonas Reconstitution of high-density lipoproteins. , 1986, Methods in enzymology.

[28]  A. Jonas,et al.  CHAPTER 17 – Lipoprotein structure , 2008 .

[29]  Thanh-Son Nguyen,et al.  All-trans-retinoic acid nanodisks. , 2007, International journal of pharmaceutics.

[30]  M. Tallman,et al.  Treatment of Acute Promyelocytic Leukemia without Cytotoxic Treatment of Acute Promyelocytic Leukemia without Cytotoxic Chemotherapy Evolution of Induction Therapy in Apl , 2022 .

[31]  L. Gordon,et al.  Curcumin nanodisk-induced apoptosis in mantle cell lymphoma , 2011, Leukemia & lymphoma.

[32]  Chad A Mirkin,et al.  Transfection of pancreatic islets using polyvalent DNA-functionalized gold nanoparticles. , 2010, Surgery.

[33]  L. Curtiss,et al.  Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma , 2010, Nature Structural &Molecular Biology.

[34]  K. Tsuchida,et al.  High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. , 2000, Biochemical and biophysical research communications.

[35]  C. McArdle,et al.  Low-density lipoprotein metabolism in mice with soft tissue tumours. , 1984, Biochimica et biophysica acta.

[36]  Chad A Mirkin,et al.  Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. , 2011, Nano letters.

[37]  L. Cupples,et al.  High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[38]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[39]  L. Gordon,et al.  Curcumin nanodisks: formulation and characterization. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[40]  A. Lacko,et al.  Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier , 2009, Journal of drug targeting.

[41]  W. Davidson,et al.  The Spatial Organization of Apolipoprotein A-I on the Edge of Discoidal High Density Lipoprotein Particles , 2003, Journal of Biological Chemistry.

[42]  Robert Langer,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[43]  A. Nègre-Salvayre,et al.  HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[44]  L. Gordon,et al.  All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma , 2010, British journal of haematology.

[45]  R. Mahley,et al.  DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY , 1980 .

[46]  W. Gross,et al.  Distribution spectrum of paraoxonase activity in HDL fractions. , 2004, Clinical chemistry.

[47]  Zahi A Fayad,et al.  Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. , 2006, Nano letters.

[48]  C. Schmidt,et al.  Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. , 1985, The Journal of biological chemistry.

[49]  E. Morrison,et al.  The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer , 2010, Cholesterol.

[50]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[51]  D. Rader,et al.  High-Density Lipoprotein Promotes Endothelial Cell Migration and Reendothelialization via Scavenger Receptor-B Type I , 2005, Circulation research.

[52]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[53]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  M. Manoharan,et al.  Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. , 2000, Nucleic acids research.

[55]  Anthony E. Klon,et al.  A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein* , 1999, The Journal of Biological Chemistry.

[56]  Colin Berry,et al.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.

[57]  R. Hegele,et al.  Is raising HDL a futile strategy for atheroprotection? , 2008, Nature Reviews Drug Discovery.

[58]  A. von Eckardstein,et al.  HDL and arteriosclerosis: beyond reverse cholesterol transport. , 2002, Atherosclerosis.

[59]  B. Hansel,et al.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia , 2005, Diabetologia.

[60]  A. Tall,et al.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Mark E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[62]  B. Williams,et al.  Efficient suppression of secretory clusterin levels by polymersiRNA polymersiRNA polymersiRNA nanocomplexes enhances ionizing radiation lethality in human MCF7 MCF7 MCF7 breast cancer cells in vitro * , 2006 .

[63]  M. Ritter,et al.  Role of apolipoprotein A-I in the structure of human serum high density lipoproteins. Reconstitution studies. , 1977, The Journal of biological chemistry.

[64]  L. Lim,et al.  " off-target " transcript silencing Position-specific chemical modification of siRNAs reduces , 2006 .

[65]  Erling Falk,et al.  Pathogenesis of atherosclerosis. , 2006, Journal of the American College of Cardiology.

[66]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  P. Wilson,et al.  High density lipoprotein cholesterol and mortality. The Framingham Heart Study. , 1988, Arteriosclerosis.

[68]  J. Benoit,et al.  The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. , 2010, Biomaterials.

[69]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[70]  D. Sviridov,et al.  Reconstituted HDL: a therapy for atherosclerosis and beyond , 2009 .

[71]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[72]  V. Tugnoli,et al.  Cholesteryl esters in malignancy. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[73]  C. E. West,et al.  Separation of plasma lipoproteins by density-gradient ultracentrifugation. , 1975, Analytical biochemistry.

[74]  Zahi A Fayad,et al.  Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. , 2004, Journal of the American Chemical Society.

[75]  G. Assmann,et al.  HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.

[76]  J. Glomset,et al.  The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.

[77]  Minghan Wang,et al.  HDL: The Metabolism, Function, and Therapeutic Importance , 2004 .

[78]  A. Miyauchi,et al.  Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. , 1999, Endocrine journal.

[79]  I. Gelissen,et al.  ABCA1 and ABCG1 Synergize to Mediate Cholesterol Export to ApoA-I , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[80]  Claudia Calcagno,et al.  Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. , 2008, Nano letters.

[81]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[82]  Y. Jo,et al.  Differential Regulation of Steroid Hormone Biosynthesis in R2C and MA-10 Leydig Tumor Cells: Role of SR-B1-Mediated Selective Cholesteryl Ester Transport1 , 2003, Biology of reproduction.

[83]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[84]  M. Siperstein Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. , 1984, Journal of lipid research.

[85]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[86]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[87]  D. Rader,et al.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.

[88]  Matthias John,et al.  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.

[89]  R. Ryan Nanodisks: hydrophobic drug delivery vehicles , 2008, Expert opinion on drug delivery.

[90]  Honglin Jin,et al.  Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. , 2011, Small.

[91]  J. Segrest,et al.  Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. , 1985, The Journal of biological chemistry.

[92]  C. Mirkin,et al.  Nanotechnology for synthetic high-density lipoproteins. , 2010, Trends in molecular medicine.

[93]  Kyung-Hyun Cho,et al.  A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation , 2009, Experimental & Molecular Medicine.

[94]  Chad A Mirkin,et al.  Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. , 2010, Bioconjugate chemistry.

[95]  Philippe Giral,et al.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. , 2004, The Journal of clinical endocrinology and metabolism.

[96]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[97]  A. Tall,et al.  High Density Lipoprotein (HDL) Particle Uptake Mediated by Scavenger Receptor Class B Type 1 Results in Selective Sorting of HDL Cholesterol from Protein and Polarized Cholesterol Secretion* , 2001, The Journal of Biological Chemistry.

[98]  B. Karten,et al.  The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. , 2000, The Biochemical journal.

[99]  M. Brown,et al.  Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. , 1978, Blood.

[100]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[101]  Jianwen Fang,et al.  Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes , 2008, Proceedings of the National Academy of Sciences.

[102]  C. Mirkin,et al.  Templated spherical high density lipoprotein nanoparticles. , 2009, Journal of the American Chemical Society.

[103]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[104]  Qingming Luo,et al.  Biomimetic nanocarrier for direct cytosolic drug delivery. , 2009, Angewandte Chemie.

[105]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[106]  F. Maxfield,et al.  Role of cholesterol and lipid organization in disease , 2005, Nature.

[107]  J. Albers,et al.  Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. , 1982, Journal of lipid research.

[108]  L. Ellis,et al.  Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. , 2011, Neoplasia.

[109]  P. Barter,et al.  The Influence of Cholesteryl Ester Transfer Protein on the Composition, Size, and Structure of Spherical, Reconstituted High Density Lipoproteins (*) , 1995, The Journal of Biological Chemistry.

[110]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[111]  A. Khera,et al.  Future Therapeutic Directions in Reverse Cholesterol Transport , 2010, Current atherosclerosis reports.

[112]  J. Sikorski 6.20 – Atherosclerosis/Lipoprotein/Cholesterol Metabolism , 2007 .

[113]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[114]  Qingming Luo,et al.  HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. , 2010, Small.

[115]  Mark E. Davis,et al.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. , 2004, European journal of cell biology.

[116]  R. Lallone,et al.  Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol , 2002, Circulation.

[117]  A. Jonas,et al.  Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. , 1982, The Journal of biological chemistry.

[118]  A. Kontush,et al.  Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities , 2010, Current opinion in lipidology.

[119]  Serkalem Demissie,et al.  Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[120]  A. Rigotti,et al.  Cellular and physiological roles of SR-BI, a lipoprotein receptor which mediates selective lipid uptake. , 2000, Biochimica et biophysica acta.

[121]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[122]  P. Libby,et al.  Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 9th Edition Expert Consult Premium Edition €“ Enhanced Online Features , 2011 .

[123]  Zahi A Fayad,et al.  The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. , 2011, Biomaterials.

[124]  Z. Fayad,et al.  An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. , 2008, Small.

[125]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[126]  Linda Mooberry,et al.  Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel , 2008, Anti-cancer drugs.

[127]  Aalt Bast,et al.  Comprehensive medicinal chemistry , 1991 .

[128]  Z. Fayad,et al.  Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. , 2009, Bioconjugate chemistry.

[129]  D. Rader,et al.  Laboratory assessment of HDL heterogeneity and function. , 2008, Clinical chemistry.

[130]  Heng Zhang,et al.  Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. , 2012, ACS nano.

[131]  T. Ishida,et al.  Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[132]  A. Tall,et al.  Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1* , 2000, The Journal of Biological Chemistry.